ProQR Therapeutics (PRQR) Total Non-Current Liabilities (2021 - 2024)
Historic Total Non-Current Liabilities for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $43.3 million.
- ProQR Therapeutics' Total Non-Current Liabilities fell 3543.17% to $43.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $43.3 million, marking a year-over-year decrease of 3543.17%. This contributed to the annual value of $43.8 million for FY2024, which is 3495.07% down from last year.
- According to the latest figures from Q4 2024, ProQR Therapeutics' Total Non-Current Liabilities is $43.3 million, which was down 3543.17% from $67.0 million recorded in Q4 2023.
- In the past 5 years, ProQR Therapeutics' Total Non-Current Liabilities registered a high of $85.3 million during Q4 2022, and its lowest value of $43.3 million during Q4 2024.
- Its 4-year average for Total Non-Current Liabilities is $68.6 million, with a median of $72.8 million in 2023.
- Per our database at Business Quant, ProQR Therapeutics' Total Non-Current Liabilities surged by 850.97% in 2022 and then crashed by 3543.17% in 2024.
- ProQR Therapeutics' Total Non-Current Liabilities (Quarter) stood at $78.7 million in 2021, then increased by 8.51% to $85.3 million in 2022, then decreased by 21.47% to $67.0 million in 2023, then tumbled by 35.43% to $43.3 million in 2024.
- Its Total Non-Current Liabilities was $43.3 million in Q4 2024, compared to $67.0 million in Q4 2023 and $85.3 million in Q4 2022.